# Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa

> **NCT02974348** · PHASE3 · COMPLETED · sponsor: **University of Bamenda** · enrollment: 300 (actual)

## Conditions studied

- Drug Resistant Malaria Due to Plasmodium Falciparum

## Interventions

- **DRUG:** Arthemeter-lumefantrine
- **DRUG:** Artesunate mefloquine
- **DRUG:** Dihydroartemisinin piperaquine
- **DRUG:** Paracetamol
- **DRUG:** Amoxicillin
- **DRUG:** Quinine

## Key facts

- **NCT ID:** NCT02974348
- **Lead sponsor:** University of Bamenda
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2013-05
- **Final completion:** 2014-10
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2016-11-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02974348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02974348, "Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02974348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*